WuXi Biologics (Cayman) Inc. (WXXWY)
- Previous Close
3.1900 - Open
3.1400 - Bid --
- Ask --
- Day's Range
3.1400 - 3.2700 - 52 Week Range
3.1400 - 13.2500 - Volume
57,476 - Avg. Volume
291,822 - Market Cap (intraday)
6.806B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
14.73 - EPS (TTM)
0.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
www.wuxibiologics.comRecent News: WXXWY
Performance Overview: WXXWY
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WXXWY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WXXWY
Valuation Measures
Market Cap
6.81B
Enterprise Value
5.88B
Trailing P/E
14.96
Forward P/E
11.32
PEG Ratio (5yr expected)
0.76
Price/Sales (ttm)
2.94
Price/Book (mrq)
1.19
Enterprise Value/Revenue
0.35
Enterprise Value/EBITDA
1.36
Financial Highlights
Profitability and Income Statement
Profit Margin
19.96%
Return on Assets (ttm)
4.63%
Return on Equity (ttm)
8.90%
Revenue (ttm)
17.03B
Net Income Avi to Common (ttm)
3.4B
Diluted EPS (ttm)
0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
11.24B
Total Debt/Equity (mrq)
10.36%
Levered Free Cash Flow (ttm)
--
Company Insights: WXXWY
WXXWY does not have Company Insights